LIME Study (LFB IVIg MMN Efficacy Study) (LIME)
A European, Randomised, Double-blind, Active Comparator Controlled, Cross-over, Efficacy and Safety Study of a New 10% Ready To-use Liquid Human Intravenous Immunoglobulin (I10E) Versus Kiovig® in Patients With Multifocal Motor Neuropathy
Sponsor: Laboratoire français de Fractionnement et de Biotechnologies
A PHASE3 clinical study on Motor Neuron Disease, this trial is completed. The trial is conducted by Laboratoire français de Fractionnement et de Biotechnologies and has accumulated 6 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Laboratoire français de Fractionnement et de Biotechnologies
- TFS Trial Form Support
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Birmingham, United Kingdom , Bordeaux, France , Créteil, France , Genova, Italy , Lille, France , Lyon, France , Marseille, France , Milan, Italy , Nice, France and 8 more locations